Barclays lowered the firm’s price target on Moderna (MRNA) to $111 from $125 and keeps an Overweight rating on the shares. The ...
Moderna (MRNA – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Tyler Van Buren ...
Investor's Business Daily on MSN6d
Moderna Slashes Hefty Premarket Gain With A Beat That's 'Not A Beat'Moderna crushed third-quarter expectations on Thursday and turned around a surprise profit. But Moderna stock pulled back ...
MRNA reports better-than-expected third-quarter earnings. It reiterates the guidance of product sales to between $3 billion ...
Moderna reported earnings that exceeded expectations due to effective cost management but still has challenges related to its ...
While Moderna’s Spikevax beat Wall Street estimates in the third quarter, William Blair analyst Myles Minter in a Thursday ...
Moderna reported a surprising third-quarter profit on Thursday, driven by cost reductions and stronger-than-expected sales of ...
Days after Pfizer and BioNTech reported surprisingly strong sales of their updated COVID-19 vaccines, Moderna has done the ...
Moderna posted Q3 2024 revenues of $1.9 billion, up from $1.8 billion in Q3 2023, with net income reaching $13 million, a turnaround from last year’s $3.6 billion loss. Growth was driven by strong US ...
Moderna reported a surprise third-quarter profit on Thursday, driven by cost cutting and higher-than-expected sales of its ...
Moderna Chief Human Resources Officer Tracey Franklin has expanded her role to Chief People and Digital Technology Officer, overseeing the Company's talent and digital functions. Brad Miller, Chief ...
Moderna stock rises as Q3 revenue beats estimates at $1.83 billion, driven by strong U.S. COVID-19 vaccine sales. EPS of $0.03 exceeds expectations.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback